Development of a highly potent anti-HBs monoclonal antibody for HBV and HDV therapy: An improvement with unsettled questions [0.03%]
一种高效抗HBs单克隆抗体开发用于治疗乙肝和丁肝：改进与未决问题共存的发展之路
Karim Mouzannar,T Jake Liang
Karim Mouzannar
Reassessing the causal relationship between liver diseases and cardiovascular outcomes [0.03%]
重新评估肝脏疾病与心血管结局之间的因果关系
Xiqiao Xiang,Yuanhao Wei,Kun Zhao
Xiqiao Xiang
Comparison of mortality outcomes in individuals with MASLD and/or MAFLD [0.03%]
与MAFLD和/或MASLD结局相关的死亡率比较分析
Qianwen Zhao,Yunlei Deng
Qianwen Zhao
A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B" [0.03%]
关于“HBeAg阴性慢性乙型肝炎患者停用核苷(酸)类似物治疗的多中心随机对照研究”的述评
Yue-Meng Wan,Hua-Mei Wu,Song-Quan Huang et al.
Yue-Meng Wan et al.
Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes [0.03%]
与纤毛发生和极性效应基因多态性相关的胆道闭锁
Joseph T Glessner,Mylarappa B Ningappa,Kim A Ngo et al.
Joseph T Glessner et al.
Background & aims: Biliary atresia (BA) is poorly understood and leads to liver transplantation (LT), with the requirement for and associated risks of lifelong immunosuppression, in most children. We performed a genome-wi...
A common variant that alters SUN1 degradation associates with hepatic steatosis and metabolic traits in multiple cohorts [0.03%]
在多个队列中与肝脂肪变性和代谢表型相关的SUN1降解变异体的共同变异体研究
Kapil K Upadhyay,Xiaomeng Du,Yanhua Chen et al.
Kapil K Upadhyay et al.
Background & aims: Non-alcoholic fatty liver disease (NAFLD), and its progressive form steatohepatitis (NASH), represent a genetically and phenotypically diverse entity for which there is no approved therapy, making it im...
What's in a name? New nomenclature for steatotic liver disease - to be or not to be? [0.03%]
何谓名称？脂肪性肝病的新命名-成为还是不成为？
Georg Semmler,Bernhard Wernly,Christian Datz
Georg Semmler
Sample types and patient preparation required when adopting the new fatty liver disease nomenclature [0.03%]
采用新的脂肪性肝病术语时所需样本类型和患者准备
Kate Elizabeth Shipman
Kate Elizabeth Shipman
Comment on 'Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized-controlled trials' [0.03%]
对“器官移植肝脏灌注技术的第一七项随机对照临床试验的荟萃分析”的评论
Gang Tang,Linyu Zhang,Rongxing Zhou
Gang Tang
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver [0.03%]
胰高糖素样肽1受体激动剂及多靶点激动剂与肝脏的影响
Philip N Newsome,Phil Ambery
Philip N Newsome
The principle pathological drivers of metabolic dysfunction-associated steatohepatitis (MASH) are obesity and associated insulin resistance, rendering them key therapeutic targets. As glucagon-like peptide 1 receptor agonists (GLP-1RAs) hav...